These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29559521)

  • 21. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
    Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
    Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
    Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
    J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
    Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
    Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
    Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
    Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S; Di Giorgio C; Distrutti E
    Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesoid X receptor and bile acids regulate vitamin A storage.
    Saeed A; Yang J; Heegsma J; Groen AK; van Mil SWC; Paulusma CC; Zhou L; Wang B; Faber KN
    Sci Rep; 2019 Dec; 9(1):19493. PubMed ID: 31862954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
    de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
    Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
    Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
    Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
    FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
    Wu H; Liu G; He Y; Da J; Xie B
    Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
    J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel function of hepatic long-chain acyl-CoA synthetase-1 (ACSL1) in bile acid synthesis and its regulation by bile acid-activated farnesoid X receptor.
    Singh AB; Dong B; Xu Y; Zhang Y; Liu J
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):358-371. PubMed ID: 30580099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
    J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.